|Bid||17.10 x 4000|
|Ask||17.11 x 4000|
|Day's range||17.09 - 17.26|
|52-week range||15.30 - 19.97|
|Beta (5Y monthly)||1.12|
|PE ratio (TTM)||13.68|
|Forward dividend & yield||0.84 (4.87%)|
|Ex-dividend date||30 Mar 2021|
|1y target est||20.42|
OSAKA, Japan & CAMBRIDGE, Mass., September 15, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based che
mRNA technology has taken the world by storm thanks to the success of two vaccine companies in 2020. What lies ahead?
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.